文献速递肿瘤 PET/CT核素与放射性配体治疗

生长抑素受体拮抗剂用于显像与治疗

Somatostatin Receptor Antagonists for Imaging and Therapy.
PubMed 文献 · J Nucl Med · 2017-01-01

本文综述放射性标记生长抑素受体(sstr)拮抗剂的发展与现状,指出基于临床前工作、人肿瘤切片定量体内放射自显影及人体数据的证据支持向sstr拮抗剂转变;JR11为选择性sstr亚型2拮抗剂,正作为68Ga标记PET显像剂和177Lu标记治疗剂进行临床开发。

要点

  • sstr显像与PET/CT可区分将从肽受体放射性核素治疗中获益的患者,支持诊疗一体化。
  • 2006年Ginj等提出放射性标记sstr拮抗剂可能优于激动剂,尽管缺乏内化。
  • 尽管头对头比较有限,sstr拮抗剂在若干情况下被证明优于激动剂。

核心结论

  • 基于临床前工作、人肿瘤切片定量体内放射自显影及人体数据的证据支持向sstr拮抗剂转变。

研究设计与样本

  • 本文为综述,讨论放射性标记sstr拮抗剂的发展与现状,涵盖临床前工作、人肿瘤切片定量体内放射自显影及人体数据。

主要发现

  • sstr显像和sstr PET/CT可区分符合条件并从肽受体放射性核素治疗中获益的患者。
  • 2006年Ginj等提出放射性标记sstr拮抗剂可能优于激动剂,尽管缺乏内化。
  • 尽管sstr拮抗剂与激动剂的头对头比较数量相当有限,sstr拮抗剂在若干情况下被证明优于激动剂。
  • JR11为选择性sstr亚型2拮抗剂,在小型sstr拮抗剂库中显示最佳总体特征,被选用于临床转化。

局限性

  • sstr拮抗剂与激动剂的头对头比较数量相当有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Somatostatin receptor (sstr) scintigraphy for imaging and sstr analogs for treatment have been used for more than 20 y. An important improvement in recent years was the introduction of peptide receptor radionuclide therapy with radiolabeled sstr agonists, such as [90Y-DOTA0,Tyr3]octreotide or [177Lu-DOTA0,Tyr3]octreotide (90Y- or 177Lu-DOTATOC, respectively) and [177Lu-DOTA0,Tyr3]octreotate (177Lu-DOTATATE). PET/CT with 68Ga-labeled sstr agonists, such as 68Ga-DOTATOC, 68Ga-DOTATATE, and [68Ga-DOTA,1-Nal3]octreotide (68Ga-DOTANOC), plays an important role in staging and restaging neuroendocrine tumors. Most importantly, sstr scintigraphy and sstr PET/CT can distinguish patients who will qualify for and benefit from peptide receptor radionuclide therapy. This characteristic of sstr targeting is important because it allows a personalized treatment approach (theranostic approach). Until recently, it was thought that internalization of the radiolabeled agonist was mandatory for sstr-mediated imaging and therapy. It was Ginj et al. who proposed in 2006 the paradigm shift that radiolabeled sstr antagonists may perform better than agonists despite the lack of internalization. Despite the rather limited number of head-to-head comparisons of sstr antagonists and agonists, the superiority of sstr antagonists was demonstrated in several cases. From a small library of sstr antagonists, the analog JR11 (Cpa-c[d-Cys-Aph(Hor)-d-Aph(Cbm)-Lys-Thr-Cys]-d-Tyr-NH2), an antagonist with selectivity for sstr subtype 2, showed the best overall characteristics for sstr subtype 2 targeting and was therefore selected for clinical translation. JR11 is under clinical development as a PET imaging agent when labeled with 68Ga (68Ga-NODAGA-JR11 or 68Ga-OPS202) and as a therapeutic agent when labeled with 177Lu (177Lu-DOTA-JR11 or 177Lu-OPS201). In this article, we discuss the development and current status of radiolabeled sstr antagonists. Evidence based on preclinical work, on quantitative in vivo autoradiography of human tumor slices, and on human data now supports a shift to sstr antagonists.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Fani M, Nicolas GP, Wild D, et al. Somatostatin Receptor Antagonists for Imaging and Therapy. J Nucl Med. 2017. PMID: 28864614. doi:10.2967/jnumed.116.186783

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。